A

license that the Department of Defense plans to issue to Sanofi Pasteur for a Zika virus vaccine is being questioned by an advocacy group over concerns the product may be priced too high for many Americans, even though it was developed with taxpayer funds. And the issue is being raised as vaccine makers chase what some believe may become a lucrative market.

Here’s the backstory: On Dec. 9, the Army placed a brief notice in the Federal Register indicating its intent to give an exclusive license to Sanofi Pasteur, one of the world’s biggest vaccine makers and a unit of the French pharmaceutical company. The move followed months of mounting alarm among public health officials over the spread of Zika, the mosquito-borne virus that can cause birth defects.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Sign up for Morning Rounds

A daily dose of health and medicine news — and a finalist for Digiday’s best email newsletter.

Recommended Stories